ArticleScientific reports2026
Prevalence and factors associated with metabolic dysfunction-associated fatty liver disease in a multiethnic Asian country.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Malaysian Society of Gastroenterology and Hepatology Consensus Statements on Prevention and Early Detection of Hepatocellular Carcinoma in Malaysia.Journal of gastroenterology and hepatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) at the general population level in Malaysia is not known. This research aimed to determine the MALFD prevalence and the associated factors among adults in the country. The study utilised a cross-sectional study design with a two-stage stratified random sampling method across all states and federal territories in Malaysia. The data collection period was between July and September 2023, which included face-to-face interviews, clinical examinations, and venepuncture. MAFLD was defined as having a fatty liver (Fatty Liver Index of 60 or more) and the fulfillment of one or more of the three conditions: obesity or overweight, two or more abnormal metabolic risks, or having diabetes. There were 1,011 participants, and the MALFD prevalence was 28.2% (95% confidence intervals of 24.6% to 32.1%). Males, those with abdominal obesity, higher diastolic blood pressure, gamma-glutamyl-transferase, alanine aminotransferase, glycosylated haemoglobin A1c, and triglycerides had higher odds of having MAFLD. The Chinese ethnicity had the lowest odds for the condition compared to the Malay ethnic group. In short, MAFLD is common and of public health interest in Malaysia. Multidisciplinary and collective actions are needed from health policymakers, public health personnel, and physicians to manage the MAFLD epidemic in the country.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.